

# **A Review of UK Guidelines for Prostate Brachytherapy**

**Sarah Aldridge**

**Head of Brachytherapy Physics**

**Guy's & St. Thomas' NHS Foundation Trust**

Guy's and St Thomas'

NHS Foundation Trust



# Overview

- Review of current guidelines for LDR & HDR prostate brachytherapy
- Incident at GSTT requiring physics advice
- How this changed our practice
- Discussion points

# Guidelines

- Fall under different categories:
  - NHS commissioning board guidance
  - Treatment planning recommendations
  - Quality assurance guidelines
  - Radiation protection advice
- Not all are published in the UK but have the involvement of UK authors and are widely accepted as the standard

# NHS Guidance

- **2013/2014 NHS Standard Contract – for brachytherapy and molecular radiotherapy**
- This is interim guidance and a review is yet to be finalised
- All brachytherapy treatments not just prostate
- For prostate discusses LDR & HDR
- This document refers to other published recommendations & guidance

# NHS Guidance

## Interstitial LDR Prostate Brachytherapy

- In line with the RCR publication in 2012, plans should be in place to concentrate this activity to meet the expectation that each oncologist should be performing 25 cases per year
- It is expected that centres delivering brachytherapy will develop plans during 2013 to meet this requirement

# NHS Guidance

## Interstitial HDR Prostate Brachytherapy

- It is expected that:
  - At least 10 patients per year are treated per centre
  - Individual clinicians and physics staff should ensure continued practical experience
  - All forms of radiotherapy are part of an overall cancer management and treatment pathway
  - Decisions on the overall treatment plan must relate back to an MDT discussion and decision

# ESTRO Guidelines

- Not published in the UK but UK authors involved and are widely accepted as the standard to follow
- **LDR prostate brachytherapy:**
  - ESTRO/EAU/EORTC recommendations on permanent seed implantation for localised prostate cancer, Rad Onc 2000, 57:315-321
- **HDR prostate brachytherapy:**
  - GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer, Rad Onc, Feb 2005, 74:137-148

# Updated Guidelines

- LDR prostate brachytherapy (2007):

Radiotherapy and Oncology 83 (2007) 3–10  
www.thegreenjournal.com

## *Guidelines prostate brachytherapy*

### Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy

Carl Salembier<sup>a</sup>, Pablo Lavagnini<sup>b</sup>, Philippe Nickers<sup>c</sup>, Paola Mangili<sup>d</sup>, Alex Rijnders<sup>a</sup>, Alfredo Polo<sup>e</sup>, Jack Venselaar<sup>f</sup>, Peter Hoskin<sup>g,\*</sup>, on behalf of the PROBATE group of GEC ESTRO

<sup>a</sup>Department of Radiation Oncology, Europe Hospitals, Brussels, Belgium, <sup>b</sup>Department of Radiation Oncology, MultiMedica Institute, Milan, Italy, <sup>c</sup>Department of Radiation Oncology, Domaine Universitaire du Sart Tilman, Liège, Belgium, <sup>d</sup>Department of Medical Physics, IRCCS, S-Raffaele, Milan, Italy, <sup>e</sup>Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain, <sup>f</sup>Department of Radiotherapy, Dr B. Verbeeten Institute, Tilburg, The Netherlands, <sup>g</sup>Mount Vernon Cancer Centre, Northwood, UK



# GEC ESTRO LDR (2007)

- The aim of this paper is to supplement the GEC/ESTRO/EAU recommendations for permanent seed implantations in prostate cancer
- Recommendations on target and organ at risk definitions
- Provides dosimetry parameters related to prescription dose for optimal treatment planning
- Provides dosimetry parameters to be reported on post implant planning

# Updated Guidelines

- HDR prostate brachytherapy (2013):

Radiotherapy and Oncology 107 (2013) 325–332



Contents lists available at SciVerse ScienceDirect

Radiotherapy and Oncology

journal homepage: [www.thegreenjournal.com](http://www.thegreenjournal.com)



GEC/ESTRO recommendations

GEC/ESTRO recommendations on high dose rate afterloading  
brachytherapy for localised prostate cancer: An update

Peter J. Hoskin<sup>a,\*</sup>, Alessandro Colombo<sup>b,1</sup>, Ann Henry<sup>c,1</sup>, Peter Niehoff<sup>d,1</sup>, Taran Paulsen Hellebust<sup>e,1</sup>,  
Frank-Andre Siebert<sup>f,1</sup>, Gyorgy Kovacs<sup>g,1</sup>

<sup>a</sup> Mount Vernon Cancer Centre, Northwood, UK; <sup>b</sup> Department of Radiotherapy, Manzoni Hospital, Lecco, Italy; <sup>c</sup> St. James Institute for Oncology, Leeds, UK; <sup>d</sup> Department of Radiotherapy, City Hospital Cologne, Germany; <sup>e</sup> DNR Norwegian Radium Hospital, Oslo, Norway; <sup>f</sup> Universitätsklinikum Schleswig-Holstein, Kiel; and <sup>g</sup> University Hospital Schleswig-Holstein Campus Lübeck, Germany

Guy's and St Thomas'

NHS Foundation Trust



# GEC ESTRO HDR (2013)

- Update of the 2005 GEC/ESTRO-EAU recommendations
- Updated to reflect emerging roles of HDR afterloading BT in prostate cancer
- Recommendations for patient selection, treatment facility, implant technique, dose prescription and dosimetry reporting are given

# Current Guidelines

- **Quality assurance practice guidelines for transperineal LDR permanent seed brachytherapy of prostate cancer, RCR Sept 2012**
- These guidelines were written by a panel of clinicians and physicists who have a large experience of LDR permanent seed prostate brachytherapy
- Guidance on training and quality assurance to produce high quality implants
- Recommends each oncologist performs 25 implants per year after an initial 3yr period

# Current Guidelines

- The role and development of afterloading brachytherapy services in the UK, RCR Sept 2012
- Review of resources for all brachytherapy treatments in the UK
- 3 areas: Gyn BT, interstitial & intraluminal and LDR seeds
- Sets out minimum standards (staffing levels, patient throughput, time frame to achieve, MDT involvement & audit)
- Refers to QA guidelines for LDR prostate BT

# Current Guidelines

- **IPEM Report 106, published 2012**
- UK Guidance on Radiation Protection Issues following Permanent Iodine-125 Seed Prostate Brachytherapy
- Purpose to give a common approach within the UK to radiation protection issues which may arise following brachytherapy to the prostate using permanent implantation of radioactive seeds
- Scenario calculations
  - Death of a patient <2yrs after implant
  - Surgical intervention
  - Doses to family members (pregnant spouse, children)

# Future Guidelines

- Recent developments for LDR permanent seed prostate brachytherapy treatments include focal treatments
- No formal guidance
- Langley et al. *Report of a consensus meeting on focal LDR brachytherapy for prostate cancer*, BJUI 109, Supplement 1, 7-16, 2012
- What about HDR focal treatments?


# Future Guidelines

- Would it be useful to have the same practice guidelines for HDR prostate brachytherapy now that its popularity has increased in the UK?
- Popularity of HDR is increasing. If centres are performing both LDR & HDR implants what should the recommended minimum number of implants per yr be?



# Physics Advice

- Incidents that I have encountered where radiation protection advice was required after a prostate seed implant:
  - Surgical intervention advice given
  - Death after a seed implant (<2yrs)
  - Salvage treatment after seed implant
  - Sexually transmitted seeds
  - Estimation of foetal dose
- Most of these incidents are covered in:
  - IPEM Report 106, 2012



# GSTT Prostate Brachytherapy

- GSTT offers prostate brachytherapy as a day case procedure which combines all aspects into a single hospital visit
- All patients treated receive radiation protection advice prior to their implant and also take home a card summarising this advice after the implant

**Radionuclide Instruction Card**  
**Prostate I-125 Implant**

Guy's and St Thomas' **NHS**  
NHS Foundation Trust

Patient's Name .....

Date of Birth .....

Address .....

.....


The holder of this card received a permanent radioactive iodine seed (Iodine - 125) implant to their prostate

Date of implant .....

Nominal seed activity ..... MBq (1mCi = 37MBq)

Total activity of implant ..... MBq

Radionuclide: Iodine - 125 (Sealed in seed form)



The holder of this card received a permanent radioactive iodine seed (Iodine - 125) implant to their prostate

**Accelyon™**

**Special Precautions**

These precautions apply for **first two months** post implant.

- Do not nurse children on your lap for long periods.
- Avoid prolonged close contact to pregnant women.
- Wear a condom during sexual intercourse.

**Other General Precautions**

- If a seed is passed, pick it up using a spoon or long handled tweezers and flush down the toilet.
- Please show this card to the doctor if you need medical treatment, as this may assist your doctor in the management of your case.
- It is safe for pelvic surgery, post mortem examinations and cremation to occur **two years** after implant.
- Please carry this card until **at least three years** after implant. After this time you may destroy it. Prior to this date please contact us on the numbers below.

Sarah Aldridge (Lead Brachytherapy Physicist) Tel: 020 7188 3792  
Paula Allchorne (Prostate Cancer Nurse) Tel: 07876 393 215  
Hospital Switchboard Tel: 020 7188 7188

Guy's and St Thomas'

NHS Foundation Trust




# Sexually Transmitted Seeds



- A patient contacted our prostate cancer nurse practitioner 3 weeks after implant informing her a lady he had been intimate with had reported symptoms of vaginal bleeding and a sore throat
- He had not used a condom as advised during sexual activities and could this be a result of an implanted seed being transferred?

# Detecting a Single Seed?

- The patient & lady in question were asked to attend clinic the next day
- Prior to the visit a mini experiment was carried out to ascertain if a single seed could be detected within a person
- Used remaining seed (activity now  $\sim 11\text{MBq}$ ) from the batch used for the actual patients implant



## Measurements with Type 44B Radiation Monitor

Bolus Thickness (cm)	Bkg	5.5	7.5	8.5	10.5	12.5	15.5
Surface (cps)	4	off scale	5000	4500	2000	850	300
20cm (cps)	4	1250	700	600	300	150	70

Measurements (cps) showed a seed could be located up to 15cm deep in a person with the radiation monitor away from the surface of the body

Guy's and St Thomas'



NHS Foundation Trust



# Assessing the Lady




The lady attended clinic:

- team discussed the situation
- sweep of her body with radiation monitor
- urine sample monitored



No seed was detected with a high degree of certainty

No radiation was detected above background levels within the urine sample



# Lessons Learned

- Raised the issue of signed consent - updated patient consent form
- Updated our patient information leaflet to explain the responsibilities patients have for others after implant
- Implemented patient seminars



Guy's and St Thomas'

NHS Foundation Trust



# Patient Seminars

## Prostate Brachytherapy

**Sarah Aldridge**

Head of Brachytherapy Physics

Guy's and St Thomas'   
NHS Foundation Trust

## Dynamic Prostate Brachytherapy – Coping with the After Effects

**Paula Allchorne**

Prostate Cancer Nurse Specialist

Guy's and St Thomas'   
NHS Foundation Trust

- Seminar length 1hr, two presentations
- Physicist – technical aspects of procedure plus radiation protection advice
- Nurse – coping with the after effects
- Patients have time to ask questions through out

Guy's and St Thomas'

NHS Foundation Trust



# Patient Satisfaction Survey

- All responders said that they would recommend the seminar to other men

*First rate seminar,  
informative and  
reassuring*


*I understand so much  
more about my  
treatment and feel much  
less scared now*

*I was too embarrassed  
to ask questions myself  
but I was able to listen  
to all the other men and  
learnt so much*

*It took the mystery  
out of the procedure  
for me*



# Patient Satisfaction Survey (50pts)

- Confident before group seminar – 62%
- More confident after group seminar – 100%
- Satisfaction with seminar – 100%
- Information overload – 0%
- Preference of individual appointments – 2%
- Not comfortable asking questions in a group setting – 6%
- Providing this education in a group setting has saved our trust money as less patient telephone conversations and a reduction in nursing hours
-  Happy confident patients

# Any Questions?



[sarah.aldridge@gstt.nhs.uk](mailto:sarah.aldridge@gstt.nhs.uk)

Guy's and St Thomas'

NHS Foundation Trust



# Opinions Required

- Recommended number of LDR & HDR procedures?
  - 25 implants per oncologist 15 LDR & 10 HDR
- HDR quality assurance guidelines?
  - Training & staffing requirements
- Focal brachytherapy guidelines?
  - LDR & HDR? Dosimetry parameters

